Aug. 6, 2025

The ACR® Center for Research and Innovation (CRI®) served as the imaging contract research organization for the DOORwaY90 clinical trial that contributed to FDA approval of Sirtex SIR-Spheres technology for liver cancer treatment.

CRI’s management of image and data collection, quality control, and central review of 600 CT/MRI scans from 65 subjects across 12 sites using five expert reviewers was critical to the success of the trial.

Interim analysis of the DOORwaY90 trial revealed that 98.5% of patients had the Best Overall Response Rate through nine months and 100% of all evaluable patients were able to demonstrate local tumor control.

Related ACR News

  • Radiology’s Fight Against Prior Authorization Delays

    ACR is leading national efforts to make prior authorization more efficient and clinically appropriate while reducing the administrative burden and supporting national legislation.

    Read more
  • ACR Supports Medicaid Coverage of Lung Cancer Screening

    ACR-backed bill would mandate Medicaid lung cancer screening, expand cessation coverage, ban prior auth—aiming to save lives and reduce disparities.

    Read more
  • Patient-Centered Imaging Care Led by Radiologists

    ACR helps its state chapters fight scope of practice expansion, such as helping to oppose bills in state legislatures that would allow non-physicians to practice independently.

    Read more